Table 1.
CpG ODN monotherapy in current clinical trials.
| Product | Type of CpG ODN | Indications | Route of Administration | Development Phase |
|---|---|---|---|---|
| CpG 7909 | Class B | Renal Cell Carcinoma | Subcutaneously | Phase I/II (NCT00043407) [93] |
| Cutaneous T-cell lymphoma | Subcutaneously | Phase I/II (NCT00043420) [94] | ||
| Melanoma, Breast Neoplasm, Renal Cell Carcinoma, T-Cell Lymphoma, NSCLC | Subcutaneously and intravenously | Phase II (NCT00043368) [95] | ||
| Melanoma | Subcutaneously | Phase II (NCT00070642) [96] | ||
| Chronic Lymphocytic Leukemia | Subcutaneously and intravenously | Phase I (NCT00233506) | ||
| Litenimod | Class B | GBM | Intracerebral | Phase II (NCT00190424) [97,98] |
| IMO-2055 | IMOs | Renal Cell Carcinoma | Subcutaneously | Phase II (NCT00729053) |
| GNKG168 | Class B | B-CLL | Intravenously | Phase I (NCT01035216) |
| ALL and AML | Intravenously | Phase I (NCT01743807) | ||
| MGN1703 | dSLIM | Advanced Colorectal Carcinoma | Subcutaneously | Phase II (NCT01208194) [99] |
| Advanced Colorectal Carcinoma | Subcutaneously | Phase III (NCT02077868) [99] | ||
| Small Cell Lung Cancer | Subcutaneously | Phase II (NCT02200081) [100] | ||
| IMO-2125 | IMOs | Solid Tumors | Intratumorally | Phase I (NCT03052205) [101] |
| Melanoma | Intradermally | Phase II (NCT04126876) | ||
| AST-008 | SNA | Solid Tumors | Intratumorally | Phase I/II (NCT03684785) |